Physician profile
Jonirai Schmidt
NPI 1427039643
$2,163.90
in general payments reported to CMS, 2019-2025
23 companies · $520 in 2025
The $520 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $334 · 2022: $282 · 2023: $490 · 2024: $537 · 2025: $520.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,548.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,547.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $654.95 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $376.90 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $279.30 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $167.11 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $139.00 | 2021-2025 | Jardiance |
| Dexcom, INC. | $79.24 | 2021-2023 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $53.04 | 2021 | |
| Exact Sciences Corporation | $45.04 | 2024-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $41.82 | 2021-2025 | Jot Dx |
| Astellas Pharma US INC | $36.29 | 2023-2025 | Veozah |
| Xeris Pharmaceuticals, INC. | $35.51 | 2025 | Gvoke Hypopen |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.30 | 2022 | |
| Inspire Medical Systems, INC. | $26.57 | 2025 | Inspire |
| Orexo US, INC. | $24.30 | 2024 | Zubsolv |
| Corcept Therapeutics | $24.18 | 2024 | Korlym |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $22.61 | 2021 | |
| Sanofi-Aventis U.S. LLC | $21.95 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $19.97 | 2021 | |
| Sanofi Pasteur INC. | $19.76 | 2022 | |
| Verona Pharma, INC. | $18.98 | 2025 | Ohtuvayre |
| Indivior INC. | $18.59 | 2021 | |
| Janssen Pharmaceuticals, INC | $15.10 | 2021 | |
| Phadia US INC. | $12.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonirai Schmidt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.